Han M, et al. - In this investigation, researchers examined concentrations of circulating neuromedin U (NMU), a highly conserved peptide, in healthy subjects and T2DM patients and assessed the link between serum NMU levels with glucose-stimulated insulin secretion. ELISA was used to analyze NMU concentrations in blood samples from newly diagnosed T2DM patients (n = 57) and age-, sex- and BMI-matched healthy control subjects (n = 50). For this analysis, they measured anthropometric parameters, oral glucose tolerance, glycosylated hemoglobin, blood lipids, insulin sensitivity, and insulin secretion. There was no difference between control subjects and newly diagnosed T2DM patients in terms of serum NMU levels. The results of the oral glucose tolerance test showed that serum NMU concentrations in both healthy controls and newly diagnosed T2DM patients did not change and did not correlate with fasting insulin levels and 1 hour, 2 hour and 3 hour after a glucose load. Overall, the investigators concluded that circulating NMU concentrations in control subjects and newly diagnosed T2DM subjects were comparable and not linked to glucose-stimulated insulin secretion.